SUBSCRIBE
SUBSCRIBE
News   Drug Development

First Half 2008 Financial Results: NicOx SA Nears Completion of Phase 3 Naproxcinod Studies

July 28, 2008 | 
1 min read
SOPHIA ANTIPOLIS, FRANCE--(Marketwire - July 28, 2008) - NicOx S.A. (Euronext Paris: COX) today reported its financial results for the six months ended June 30, 2008.
Clinical research Phase 3 Earnings Europe
MORE ON THIS TOPIC
Target concept vector illustration. Business goal, marketing strategy, digital aim, bullseye accuracy, cyber challenge, innovation target, focus objective, dart board, internet market.
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
 · 
3 min read
 · 
Gabrielle Masson
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
Words IPO (Initial public offering) with the trading data on the background.
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
 · 
1 min read
 · 
Gabrielle Masson